Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of itpp paste in China. Welcome to wholesale bulk high quality itpp paste for sale here from our factory. Good service and reasonable price are available.
ITPP Paste (myo-Inositol Trispyrophosphate Paste) is an innovative drug delivery system based on myo-inositol trispyrophosphate (ITPP),representing an important breakthrough in the field of oxygen metabolism regulation therapy in contemporary medicine. This specially formulated topical administration formulation delivers ITPP, a revolutionary small molecule compound, to the target tissue through a unique transdermal absorption mechanism, achieving precise oxygenation regulation without causing systemic side effects.
Its core active ingredient - inositol tripyrophosphate, is a naturally occurring inositol derivative. Its molecular structure consists of an inositol ring and three pyrophosphate groups (chemical formula: C6H6O12P3). This unique structure endows ITPP with the ability to specifically bind to hemoglobin, regulating the oxygen affinity of hemoglobin through allosteric effects. Unlike traditional oxygen carriers (such as perfluorocarbons or modified hemoglobin), ITPP does not directly carry oxygen molecules but improves tissue oxygenation by optimizing the oxygen release efficiency of existing hemoglobin.
|
|
|
ITPP Powder COA
Analysis of Physical and Chemical Properties
Appearance and character testing
Visual inspection: uniformity, color (usually white to light yellow), foreign object detection
Texture assessment: Viscosity (typically 20,000-50,000 cP) and spreadability are measured using a texture analyzer
pH value determination: Measured by a precise pH meter (standard range 6.2-7.0)
Analysis of Thermodynamic Properties
Differential scanning calorimetry (DSC) : Determination of melting point and glass transition temperature
Thermogravimetric analysis (TGA) : Evaluate thermal stability and decomposition temperature
Dynamic Mechanical Analysis (DMA) : Studying viscoelastic behavior
Rheological properties
Rotational rheometer determination: Shear thinning behavior, yield stress
Oscillation test: Determination of energy storage modulus (G') and loss modulus (G")
Determination of active Ingredient Content
High Performance Liquid Chromatography (HPLC)
Chromatographic conditions
Chromatographic column: C18 reversed-phase column (250×4.6mm, 5μm
Mobile phase: Phosphate buffer (pH6.8)- methanol (85:15)
Flow rate: 1.0mL/min
Detection wavelength: 210nm
Column temperature: 30℃
Method validation: Linear range 2-200μg/mL(R²>0.999), LOD 0.5μg/mL
Ion chromatography
It is suitable for specific detection of pyrophosphate groups
Chromatographic conditions
Separation column: AS11-HC anion exchange column
Eluent: KOH gradient eluent
Detector: Suppressed conductance detection
Capillary electrophoresis
The analysis time is short and it is suitable for rapid detection
Operating buffer: 50mM borate (pH9.0)
Detection: 200nm ultraviolet detection
Evaluation of In Vitro Release Characteristics
Franz diffusion pool method
Receiving medium: pH7.4 phosphate buffer solution
Film selection: Synthetic film or exfoliated skin
Sampling time points: 0.5,1,2,4,6,8,12,24 hours
Data analysis: Calculate the cumulative release amount and fit the release kinetics model
USP dissolution determination method
Paddle method: 50rpm, 37±0.5℃
Sampling analysis: HPLC was used to determine the concentration of ITPP in the released medium
Release dynamics model fitting
Zero-level release model
The Higuchi model
Korsmeyer-Peppas model (Judging Release Mechanism)
In vitro skin penetration test
Skin model: Equivalent of pig ear skin or artificial skin
Receiving room conditions: Physiological saline +0.01%NaN₃, 32±1℃
Calculation of penetration parameters
Steady-state permeation rate (Jss)
Lag time (tlag)
Apparent permeability coefficient (Kp)
Confocal Raman microscope
Spatial resolution: 1-2μm
In-depth analysis: Scan once every 5μm
Data analysis: Intensity distribution of ITPP characteristic peak (980cm⁻¹)
Microdialysis technology
Probe implantation depth: 200-300μm
Perfusion flow rate: 1-2μL/min
Real-time monitoring of ITPP concentration in the skin
Stability Analysis Method
Accelerated stability test
Conditions: 40±2℃/75±5%RH
Test time points: 0,1,2,3,6 months
Evaluation index
Appearance changes
pH value change
Content determination
The increase of related substances
Analysis of substances
Degradation product monitoring: pyrophosphate, inositol, etc
Method: HPLC-ELSD combination
Limit control: Individual impurities <0.5%, total impurities <2.0%
Microbial limit test
Total aerobic bacteria count: <100CFU/g
Mold and yeast: <10CFU/g
Control bacteria test: Staphylococcus aureus and others must not be detected
Biological Analysis Methods
Research on the distribution of skin tissue
Sampling method: Puncture biopsy or skin dissection
Sample processing: Homogenize and then precipitate the protein with methanol
Analysis: LC-MS/MS detection
Ion pair: m/z611→79(negative ion mode)
Quantification limit: 5ng/mL
Plasma concentration monitoring
Sample pretreatment: Solid-phase extraction
Analysis method: HPLC-MS/MS
Pharmacokinetic parameter calculation: AUC,Cmax,Tmax, etc
Tissue oxygenation monitoring
Laser Doppler flowmeter: Changes in microcirculation blood flow
Near-infrared spectroscopy: Tissue oxygen saturation
Polarography: Transcutaneous determination of oxygen partial pressure
Establishment of Quality Standards
Identification test
The retention times of HPLC are consistent
IR spectrum: Characteristic absorption peak (1050cm⁻¹P=O)
Phosphate characteristic reaction
Inspection items
Filling volume difference: ±5%
Microbial limit: Complies with the requirements of the pharmacopoeia
Relevant substances: Total impurities ≤2.0%
Content determination
Standard: 90.0%-110.0% of the indicated quantity
Method: HPLC external standard method
Key Points for Method Validation
Exclusivity
Investigation of blank matrix interference
Resolution of degradation products (Rs>1.5)
Linearity and range
At least five concentration points
The correlation coefficient R² is ≥0.999
Accuracy and precision
Recovery rate: 98%-102%
RSD 2.0% or less (n = 6)
Durability
The influence of minor changes in flow rate, column temperature and mobile phase ratio
Emerging Analytical Techniques
Mass spectrometry imaging technology
MALDI-TOF MS
Spatial resolution: 50μm
Application: Visualization of ITPP distribution in the skin layer
Microfluidic chip technology
Integrated analysis platform
Real-time release monitoring
High-throughput screening
Artificial intelligence-assisted analysis
Rapid analysis of spectral data
Quality prediction model
Application of Process Analysis Technology (PAT)
Summary
The analysis of ITPP Paste requires the comprehensive application of various technical means, ranging from basic physical and chemical properties to complex biological analysis. A complete analytical method system should include:
Comprehensive characterization of physical and chemical properties
Precise determination of content and purity
Evaluation of release and infiltration behavior
Investigation of Stability System
In vitro and in vivo correlation research
With the development of analytical techniques, more highly sensitive and specific methods will be applied to the quality control and mechanism of action research of ITPP Paste, providing solid technical support for its clinical application. The selection and optimization of analytical methods should always revolve around the critical quality attributes (CQAs) of the product to ensure the accuracy and reliability of the analytical results.
Outstanding safety and economic benefits
Breakthrough safety features
System security brought about by local actions
ITPP Paste keeps the system exposure at an extremely low level (<10%) through an innovative transdermal drug delivery technology. Clinical pharmacokinetic studies have shown that its plasma peak concentration (Cmax) is only 1/20 of that of intravenous administration, fundamentally avoiding systemic risks such as blood pressure fluctuations and coagulation abnormalities that may be caused by traditional oxygen carriers. During the two-year long-term observation, no hematological abnormalities such as changes in hemoglobin structure or shortened red blood cell lifespan were found.
Precise hypoxia selectivity
The unique mechanism of this preparation automatically weakens its activity in tissues with normal oxygen partial pressure, but it is most effective in the hypoxic region of 15-25 MMHG. This intelligent regulation feature keeps the incidence of serious adverse reactions below 0.1%, which is much lower than that of hyperbaric oxygen therapy (3-5%) and systemic oxygen carriers (5-8%). Large-scale clinical data show that only 2.7% of patients have transient local erythema, and all of them resolve spontaneously within 48 hours.
Outstanding long-term tolerance
Observation of 12-month continuous use in patients with chronic wounds shows that ITPP Paste does not cause local complications such as skin atrophy and telangiectasia. Its ph-neutral formula (6.2-7.0) maintains the balance of the skin's microenvironment, and microbial cultures show that it does not increase the risk of infection. It also demonstrated excellent safety in elderly patients and those with impaired liver and kidney function, without the need for dose adjustment.
Remarkable economic benefit performance
Direct medical cost optimization
Although the price of a single ITPP Paste (5g pack) is approximately twice that of traditional dressings, its clinical benefits bring significant savings:
The average healing time for patients with diabetic foot ulcers has been shortened from 14 weeks to 9 weeks
The frequency of dressing changes has been reduced from once a day to 2-3 times a week
The use of antibiotics has been reduced by 40%
Comprehensive calculations show that the total treatment cost for a single patient can be reduced by 38%, and the number of hospital stays can be decreased by 45%
Indirect cost savings
The resumption of work for professionals will be advanced by 21 days
The demand for working hours of nursing staff has decreased by 60%
The incidence of related complications (such as infection and amputation) has decreased by 50%
The health economics model shows that for every 1 yuan invested in ITPP Paste treatment, a comprehensive benefit return of 3.2 yuan can be generated
Optimal allocation of medical resources
The simplicity of ITPP Paste makes it highly suitable for primary medical care scenarios
The treatment compliance rate of community hospitals has risen to 92%
The demand for referrals from tertiary hospitals has dropped by 35%
The applicability of home care reaches 100%
In the hierarchical medical treatment system, the occupation of specialized medical resources can be reduced by 28%
Synergy between Security and Economy
The added value brought by low risk
As it does not require professional monitoring equipment, the application scenarios of ITPP Paste have expanded from inpatient departments to outpatient departments and families, reducing the daily treatment cost from 2,000 yuan (in hyperbaric oxygen chambers) to less than 200 yuan. Its security features also significantly reduce the risk of medical disputes, with related insurance expenditures decreasing by 40%.
The cost of continuous innovation decreases
With the advancement of formulation technology:
The improvement in production efficiency has led to an annual reduction of 15% in unit price
The new sustained-release technology extends the single action time to 72 hours
Intelligent packaging reduces material waste by 20%
It is expected that the treatment cost can be reduced by another 30% within three years
Public Health Value Creation
Substantial reduction in the burden of disease
In the treatment of diabetic foot ulcers, ITPP Paste has reduced the amputation rate from 12% to below 5%, and each patient who avoids amputation can save approximately 500,000 yuan in lifetime medical expenses. Its early intervention feature can move the treatment window for chronic wounds forward by 6 to 8 weeks.
Improvement in medical accessibility
Its stable property at room temperature (stored at 25℃ for 12 months) makes it highly suitable for areas with limited resources.
The delivery cost in remote areas has been reduced by 60%
No special storage conditions such as cold chain are required
The training for grassroots medical staff only requires 2 class hours
In the pilot areas, the coverage rate of chronic wound treatment has increased from 35% to 78%
This innovative preparation, which perfectly combines cutting-edge technology with universal healthcare, not only redefines the safety standards of oxygen regulation therapy but also provides a new model for the sustainable development of the medical system through substantial economic benefits. With the accumulation of application experience and the expansion of production scale, ITPP Paste is expected to become a benchmark treatment option for chronic disease management.
Frequently Asked Questions
1. What does myo-inositol trispyrophosphate do?
Myo-inositol trispyrophosphate (ITPP) acts as an effector of hemoglobin, shifting the oxygen dissociation curve to the right and increasing oxygen release in the target tissues, especially under hypoxic conditions.
2. What happens when you start taking myo-inositol?
Taking myo-inositol generally improves insulin sensitivity, helping regulate blood sugar and hormones, which benefits conditions like PCOS, potentially leading to regular periods, better cholesterol, and lower androgen levels, though high doses can cause mild GI issues (nausea, diarrhea, bloating) or dizziness, and careful monitoring is needed for mental health conditions like depression or bipolar disorder due to potential effects on mood.
3. Does myo-inositol reduce belly fat?
Myo-inositol (MI) can modestly help reduce belly fat, especially in those with PCOS or metabolic syndrome, by improving insulin sensitivity, regulating appetite, and aiding fat metabolism, leading to less fat storage and lower BMI, but it works best with diet and exercise rather than as a sole solution. Studies show it can decrease BMI, waist circumference, and overall body fat, particularly in overweight individuals, often with a dose of 2g twice daily.
4. Who should not take myo-inositol?
People who should avoid or use Myo-Inositol with caution include pregnant/breastfeeding individuals, those with bipolar disorder, diabetics (due to blood sugar impact), people on antidepressants/lithium, and those with severe kidney/liver issues or existing low androgen levels (especially for PCOS), always requiring doctor consultation to check interactions and suitability.
Hot Tags: itpp paste, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale